Zimmer Biomet Holdings, Inc.
General ticker "ZBH" information:
- Sector: Health Care
- Industry: Medical - Devices
- Capitalization: $18.0B (TTM average)
Zimmer Biomet Holdings, Inc. follows the US Stock Market performance with the rate: 1.7%.
Estimated limits based on current volatility of 1.2%: low 93.01$, high 95.21$
Factors to consider:
- Company included in S&P500 list
- Company pays dividends (quarterly): last record date 2026-09-30, amount 0.24$ (Y1.01%)
- Total employees count: 17000 (0.0%) as of 2025
- US accounted for 57.8% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Market competition, Regulatory and compliance, Supply chain disruptions, Cybersecurity threats, Acquisition/divestiture risks
- Price in estimated range
- Earnings for 6 months up through Q2 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [75.60$, 113.66$]
- 2026-12-31 to 2027-12-31 estimated range: [76.90$, 115.51$]
Financial Metrics affecting the ZBH estimates:
- Negative: with PPE of 11.0 at the end of fiscal year the price was high
- Positive: 11.29 < Operating profit margin, % of 13.34
- Positive: 8.77 < Operating cash flow per share per price, % of 9.50
- Positive: Industry inventory ratio change (median), % of 0.70 <= 1.15
- Positive: 49.86 < Shareholder equity ratio, % of 54.99 <= 58.56
- Negative: Industry earnings per price (median), % of -3.46 <= 0
- Negative: negative Industry operating cash flow (median)
- Positive: -51.61 < Industry operating profit margin (median), % of -29.60
- Positive: Inventory ratio change, % of -0.81 <= -0.37
- Positive: 1.88 < Return on assets ratio (scaled to [-100,100]) of 2.96
Short-term ZBH quotes
Long-term ZBH plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $7,394.20MM | $7,678.60MM | $8,231.50MM |
| Operating Expenses | $6,116.50MM | $6,392.90MM | $7,133.40MM |
| Operating Income | $1,277.70MM | $1,285.70MM | $1,098.10MM |
| Non-Operating Income | $-210.40MM | $-249.10MM | $-267.30MM |
| Interest Expense | $201.20MM | $218.00MM | $292.80MM |
| R&D Expense | $458.70MM | $437.40MM | $458.50MM |
| Income(Loss) | $1,067.30MM | $1,036.60MM | $830.80MM |
| Taxes | $42.20MM | $131.40MM | $125.70MM |
| Net Income(Loss)* | $1,024.00MM | $903.80MM | $705.20MM |
| Stockholders Equity | $12,480.50MM | $12,468.10MM | $12,697.70MM |
| Inventory | $2,385.20MM | $2,235.30MM | $2,286.40MM |
| Assets | $21,496.90MM | $21,365.30MM | $23,091.70MM |
| Operating Cash Flow | $1,581.60MM | $1,499.40MM | $1,697.10MM |
| Capital expenditure | $394.50MM | $356.80MM | $224.50MM |
| Investing Cash Flow | $-778.90MM | $-888.10MM | $-1,975.70MM |
| Financing Cash Flow | $-763.50MM | $-484.50MM | $326.00MM |
| Earnings Per Share** | $4.91 | $4.45 | $3.56 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.